|
US8258163B2
(en)
|
2008-06-04 |
2012-09-04 |
Board Of Regents, The University Of Texas System |
Small-molecule agonists for type-2 orexin receptor
|
|
US9527807B2
(en)
|
2011-04-05 |
2016-12-27 |
Takeda Pharmaceutical Company Limited |
Sulfonamide derivative and use thereof
|
|
EP2836485B1
(en)
|
2012-03-17 |
2018-01-10 |
Polyphor Ag |
Conformationally constrained, fully synthetic macrocyclic compounds
|
|
WO2014198880A1
(en)
|
2013-06-14 |
2014-12-18 |
Ferrer Internacional, S.A. |
2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
|
|
US20160250224A1
(en)
|
2013-09-24 |
2016-09-01 |
The Board Of Regents Of The University Of Texas System |
Orexin-control of bone formation and loss
|
|
WO2015073707A1
(en)
|
2013-11-15 |
2015-05-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating heart failure with agonists of hypocretin receptor 2
|
|
SG11201604639YA
(en)
|
2013-12-12 |
2016-07-28 |
Univ Tsukuba |
Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof
|
|
JP6552117B2
(ja)
|
2014-03-28 |
2019-07-31 |
国立大学法人 筑波大学 |
敗血症の予防治療剤
|
|
JP6715239B2
(ja)
|
2014-09-11 |
2020-07-01 |
ヤンセン ファーマシューティカ エヌ．ベー． |
置換２−アザ二環式化合物及びオレキシン受容体調節因子としてのその使用
|
|
WO2016133160A1
(ja)
|
2015-02-19 |
2016-08-25 |
国立大学法人筑波大学 |
スルホンアミド誘導体またはその薬学的に許容される酸付加塩
|
|
CA2989146A1
(en)
|
2015-06-12 |
2016-12-15 |
Board Of Regents, The University Of Texas System |
Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof
|
|
SG11201806429PA
(en)
|
2016-02-04 |
2018-08-30 |
Takeda Pharmaceuticals Co |
Substituted piperidine compound and use thereof
|
|
JP7012703B2
(ja)
|
2017-03-08 |
2022-02-14 |
武田薬品工業株式会社 |
置換ピロリジン化合物およびその用途
|
|
JP6957598B2
(ja)
|
2017-03-08 |
2021-11-02 |
武田薬品工業株式会社 |
置換ピロリジン化合物およびその用途
|
|
US11319286B2
(en)
|
2017-08-03 |
2022-05-03 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and application thereof
|
|
US10428023B2
(en)
|
2017-08-03 |
2019-10-01 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and use thereof
|
|
CN111132975B
(zh)
|
2017-09-28 |
2023-05-23 |
勃林格殷格翰国际有限公司 |
N-(2,2-二氟乙基)-n-[(嘧啶基氨基)丙基]芳基甲酰胺
|
|
JP7170996B2
(ja)
|
2017-12-12 |
2022-11-15 |
国立大学法人 筑波大学 |
スルホンアミド誘導体またはその薬学的に許容される酸付加塩
|
|
WO2019191327A1
(en)
|
2018-03-27 |
2019-10-03 |
Board Of Regents, The University Of Texas System |
Ox2r compounds
|
|
EP3816154B1
(en)
|
2018-06-29 |
2025-04-23 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and application thereof
|
|
US11655241B2
(en)
|
2018-06-29 |
2023-05-23 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and use thereof
|
|
JP7379374B2
(ja)
|
2018-12-12 |
2023-11-14 |
武田薬品工業株式会社 |
複素環化合物
|
|
JP7408569B2
(ja)
|
2018-12-12 |
2024-01-05 |
武田薬品工業株式会社 |
複素環化合物
|
|
PE20211700A1
(es)
|
2019-01-31 |
2021-09-01 |
Takeda Pharmaceuticals Co |
Compuesto heterociclico y su uso
|
|
US11098029B2
(en)
|
2019-02-13 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
5-alkyl pyrrolidine orexin receptor agonists
|
|
WO2020167701A1
(en)
|
2019-02-13 |
2020-08-20 |
Merck Sharp & Dohme Corp. |
Pyrrolidine orexin receptor agonists
|
|
EP4010314B1
(en)
|
2019-08-08 |
2024-02-28 |
Merck Sharp & Dohme LLC |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
|
JP2022547604A
(ja)
|
2019-09-13 |
2022-11-14 |
武田薬品工業株式会社 |
過度の眠気の治療のためのオレキシン２受容体アゴニストの使用
|
|
KR20260083444A
(ko)
|
2019-11-25 |
2026-06-05 |
알케르메스,인코포레이티드 |
치환된 마크로사이클릭 화합물 및 관련 치료 방법
|
|
WO2021106975A1
(ja)
|
2019-11-27 |
2021-06-03 |
武田薬品工業株式会社 |
複素環化合物
|
|
US11352357B2
(en)
|
2019-11-27 |
2022-06-07 |
Sumitomo Dainippon Pharma Co., Ltd. |
Cycloalkylurea derivative
|
|
CA3167050A1
(en)
|
2020-01-10 |
2021-07-15 |
Takeda Pharmaceutical Company Limited |
A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome p450
|
|
CN119235864A
(zh)
|
2020-07-17 |
2025-01-03 |
卫材R&D管理有限公司 |
取代的哌啶化合物及其用途
|
|
US20230365533A1
(en)
|
2020-08-18 |
2023-11-16 |
Merck Sharp & Dohme Llc |
Bicycloheptane pyrrolidine orexin receptor agonists
|
|
WO2022040058A1
(en)
|
2020-08-18 |
2022-02-24 |
Merck Sharp & Dohme Corp. |
Cyclopentapyrrole orexin receptor agonists
|
|
CN116635393A
(zh)
|
2020-09-03 |
2023-08-22 |
欧瑞夏治疗有限公司 |
中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途
|
|
US12503475B2
(en)
|
2020-09-03 |
2025-12-23 |
Centessa Pharmaceuticals (Uk) Limited |
Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
|
|
JP2022064180A
(ja)
|
2020-10-13 |
2022-04-25 |
武田薬品工業株式会社 |
複素環化合物
|
|
WO2022094012A1
(en)
|
2020-11-02 |
2022-05-05 |
Merck Sharp & Dohme Corp. |
Macrocyclic urea orexin receptor agonists
|
|
EP4247801A4
(en)
|
2020-11-23 |
2024-10-30 |
Merck Sharp & Dohme LLC |
3-AMINO PYRROLIDINE AND MACROCYCLIC PIPERIDINE OREXIN RECEPTOR AGONISTS
|
|
US12552767B2
(en)
|
2020-12-03 |
2026-02-17 |
Merck Sharp & Dohme Llc |
3-heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
|
US12692262B2
(en)
|
2020-12-16 |
2026-07-28 |
Merck Sharp & Dohme Llc |
Substituted ureas as orexin receptor agonists
|
|
US12006330B2
(en)
*
|
2020-12-21 |
2024-06-11 |
Alkermes, Inc. |
Substituted macrocyclic compounds and related methods of treatment
|
|
JP7860139B2
(ja)
|
2021-03-03 |
2026-05-15 |
リサーチ トライアングル インスティテュート |
オレキシン受容体アゴニストとしてのアリールスルホンアミド
|
|
WO2022207935A1
(en)
|
2021-04-02 |
2022-10-06 |
Orexia Therapeutics Limited |
2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
|
|
MX2023012971A
(es)
|
2021-05-03 |
2024-01-16 |
Jazz Pharmaceuticals Ireland Ltd |
Agonistas del receptor de orexina y sus usos.
|
|
JPWO2022250108A1
(enExample)
|
2021-05-26 |
2022-12-01 |
|
|
|
EP4359387A1
(en)
|
2021-06-25 |
2024-05-01 |
Jazz Pharmaceuticals Ireland Limited |
Sulfonamide orexin receptor agonists and uses thereof
|
|
WO2023017180A1
(en)
|
2021-08-13 |
2023-02-16 |
Orexia Therapeutics Limited |
Peptide derivatives and related uses as orexin agonists
|